Gao Xun, Zhang Yue, Li Tingting, Li Jioajiao, Su Yingying, Wang Hongsen, Yan Zhankuan, Qin Kunming
Jiangsu Key Laboratory of Marine Bioresources and Environment, Jiangsu Ocean University, Lianyungang, 222005, China; Co-Innovation Center of Jiangsu Marine Bio-Industry Technology, Jiangsu Ocean University, Lianyungang, 222001, China; School of Pharmacy, Jiangsu Ocean University, Lianyungang, 222005, China.
Jiangsu Key Laboratory of Marine Bioresources and Environment, Jiangsu Ocean University, Lianyungang, 222005, China; Co-Innovation Center of Jiangsu Marine Bio-Industry Technology, Jiangsu Ocean University, Lianyungang, 222001, China; School of Pharmacy, Jiangsu Ocean University, Lianyungang, 222005, China.
Anal Biochem. 2023 Aug 15;675:115214. doi: 10.1016/j.ab.2023.115214. Epub 2023 Jun 21.
Fructus Choerospondiatis (FC), a Mongolian medicine, was mainly used in Mongolian medical theory for the treatment of coronary heart disease (CHD). Nonetheless, the main components and mechanisms of action of FC in the treatment of coronary artery disease have not been studied clearly.
The aim of this study is to identify the components of FC and analyze the pathways affected by the targets of these components to probe into the potential mechanisms of action of FC on coronary heart disease.
Identification of compounds in FC employing high performance liquid chromatography quadrupole time-of-flight tandem mass spectrometry (HPLC-QTOF-MS) method, then further investigate the network pharmacology and molecular docking to obtain potential targets and elucidate the potential mechanism of action of FC in the therapy of CHD. Experimental validation was established to verify the mechanism of FC in vitro.
21 FC components were identified and 65 overlapping targets were gained. In addition, these ingredients regulated AMPK and PPAR signaling pathway by 65 target genes including IL6, AKT1 and PPARg, etc. Molecular docking displayed that the binding ability of the key target PPARg to FC components turned out to be better. Experimental validation proved that FC treatment decreased the expression of PPARg (p < 0.05) compare with model group, which may be involved in the PPAR signaling pathway.
This study was the first to elucidate the mechanism of action of components of FC for the treatment of CHD using network pharmacology. It alleviated CHD by inhibiting the expression of PPARg to attenuate hypoxia/reoxygenation injury, and the results give a basis for elucidating the molecular mechanism of action of FC for the treatment of coronary heart disease.
南酸枣，一种蒙药，在蒙医理论中主要用于治疗冠心病（CHD）。然而，南酸枣治疗冠状动脉疾病的主要成分和作用机制尚未明确。
本研究旨在鉴定南酸枣的成分，并分析这些成分靶点所影响的通路，以探究南酸枣治疗冠心病的潜在作用机制。
采用高效液相色谱-四极杆飞行时间串联质谱（HPLC-QTOF-MS）法鉴定南酸枣中的化合物，进而通过网络药理学和分子对接研究获得潜在靶点，并阐明南酸枣治疗冠心病的潜在作用机制。建立实验验证以在体外验证南酸枣的作用机制。
鉴定出21种南酸枣成分，获得65个重叠靶点。此外，这些成分通过包括IL6、AKT1和PPARg等在内的65个靶基因调节AMPK和PPAR信号通路。分子对接显示关键靶点PPARg与南酸枣成分的结合能力更强。实验验证证明，与模型组相比，南酸枣处理可降低PPARg的表达（p < 0.05），这可能与PPAR信号通路有关。
本研究首次利用网络药理学阐明了南酸枣成分治疗冠心病的作用机制。它通过抑制PPARg的表达减轻缺氧/复氧损伤来缓解冠心病，研究结果为阐明南酸枣治疗冠心病的分子作用机制提供了依据。
